NO20032781L - Anvendelse av overekspresjon av laminin-alfa-4-subenhet som en diagnostiskog prognostisk indikator for maligne tumorer - Google Patents

Anvendelse av overekspresjon av laminin-alfa-4-subenhet som en diagnostiskog prognostisk indikator for maligne tumorer

Info

Publication number
NO20032781L
NO20032781L NO20032781A NO20032781A NO20032781L NO 20032781 L NO20032781 L NO 20032781L NO 20032781 A NO20032781 A NO 20032781A NO 20032781 A NO20032781 A NO 20032781A NO 20032781 L NO20032781 L NO 20032781L
Authority
NO
Norway
Prior art keywords
laminin
overexpression
subunit
malignant tumors
diagnostic
Prior art date
Application number
NO20032781A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032781D0 (no
Inventor
Julia Y Ljubimova
Alexander V Ljubimov
Keith L Black
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of NO20032781D0 publication Critical patent/NO20032781D0/no
Publication of NO20032781L publication Critical patent/NO20032781L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20032781A 2000-12-19 2003-06-18 Anvendelse av overekspresjon av laminin-alfa-4-subenhet som en diagnostiskog prognostisk indikator for maligne tumorer NO20032781L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/741,550 US20020155440A1 (en) 2000-12-19 2000-12-19 Using overexpression of laminin alpha 4 subunit as a diagnostic and prognostic indicator of malignant tumors
PCT/US2001/050292 WO2002059610A2 (en) 2000-12-19 2001-12-19 Lamin alpha 4 subunit as a diagnostic indicator of malignant tumors

Publications (2)

Publication Number Publication Date
NO20032781D0 NO20032781D0 (no) 2003-06-18
NO20032781L true NO20032781L (no) 2003-08-18

Family

ID=24981166

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032781A NO20032781L (no) 2000-12-19 2003-06-18 Anvendelse av overekspresjon av laminin-alfa-4-subenhet som en diagnostiskog prognostisk indikator for maligne tumorer

Country Status (7)

Country Link
US (1) US20020155440A1 (pl)
EP (1) EP1356294A2 (pl)
IL (1) IL156541A0 (pl)
NO (1) NO20032781L (pl)
PL (1) PL366317A1 (pl)
WO (1) WO2002059610A2 (pl)
ZA (1) ZA200305097B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
US7877273B2 (en) * 2002-01-08 2011-01-25 Fredric David Abramson System and method for evaluating and providing nutrigenomic data, information and advice
WO2004048548A2 (en) * 2002-11-25 2004-06-10 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
US20050053958A1 (en) * 2002-11-25 2005-03-10 Roth Richard B. Methods for identifying risk of breast cancer and treatments thereof
AU2003293130A1 (en) * 2002-11-25 2004-06-18 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
US20050272043A1 (en) * 2003-07-24 2005-12-08 Roth Richard B Methods for identifying risk of breast cancer and treatments thereof
JP4567683B2 (ja) * 2003-09-12 2010-10-20 セダーズ−シナイ メディカル センター ヒトグリオームを阻害するための、ラミニン−８発現のアンチセンス阻害
JP5008981B2 (ja) * 2003-12-05 2012-08-22 アロジーン， インコーポレイテッド ポリリンゴ酸ベースの多機能性薬物送達システム
US8911717B2 (en) 2003-12-05 2014-12-16 Cedars-Sinai Medical Center Polymalic acid-based multifunctional drug delivery system
US20050227225A1 (en) * 2004-04-07 2005-10-13 Roche Molecular Systems, Inc. Stabilization of biomolecules in samples
CA2567973A1 (en) * 2004-05-27 2005-12-15 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
CA2661633A1 (en) * 2006-09-06 2008-03-13 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
US8530415B2 (en) * 2008-01-30 2013-09-10 Histogen, Inc. Repair and/or regeneration of cells with a composition produced by culturing fibroblast cells under hypoxic conditions
US8535913B2 (en) * 2008-01-30 2013-09-17 Histogen, Inc. Soluble composition for promoting hair growth produced by hypoxic culture of fibroblasts cells
US8524494B2 (en) 2008-01-30 2013-09-03 Histogen, Inc. Low oxygen tension and BFGF generates a multipotent stem cell from a fibroblast in vitro
CA2714387C (en) * 2008-01-30 2018-06-19 Histogen, Inc. Extracellular matrix compositions
CA2716357A1 (en) * 2008-03-05 2009-09-11 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
RU2393773C1 (ru) * 2009-04-20 2010-07-10 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ УЧРЕЖДЕНИЕ РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ВЫСОКОТЕХНОЛОГИЧНОЙ МЕДИЦИНСКОЙ ПОМОЩИ (ФГУ "РНЦРХТ Росмедтехнологий") Способ прогнозирования продолжительности жизни больных глиальными опухолями головного мозга
CN102482698B (zh) * 2009-07-10 2018-09-25 希斯托金公司 条件培养基和来自低氧含量条件下培养的细胞的胞外基质组合物
EP2509421B1 (en) 2009-12-10 2020-02-05 Cedars-Sinai Medical Center Drug delivery of temozolomide for systemic based treatment of cancer
RU2433410C2 (ru) * 2009-12-25 2011-11-10 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" Способ прогнозирования развития направленности патологического процесса у больных с опухолями головного мозга
RU2441599C1 (ru) * 2010-09-09 2012-02-10 Государственное учреждение Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского (ГУ МОНИКИ им. М.Ф. Владимирского) Способ выбора тактики лечения больных с глиомами низкой степени злокачественности
US9623041B2 (en) 2010-12-30 2017-04-18 Cedars-Sinai Medical Center Polymalic acid-based nanobiopolymer compositions
EP2694117A4 (en) * 2011-04-06 2014-06-11 Cedars Sinai Medical Center IMAGING NANOCONJUGATES BASED ON POLYMALE ACID
CN107058596A (zh) * 2017-06-19 2017-08-18 上海市第十人民医院 一种与恶性胶质瘤诊断相关的标志物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5905027A (en) * 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
US20020076736A1 (en) * 2000-05-12 2002-06-20 Findell Paul R. Methods of affecting laminin 5 processing

Also Published As

Publication number Publication date
IL156541A0 (en) 2004-01-04
US20020155440A1 (en) 2002-10-24
PL366317A1 (pl) 2005-01-24
EP1356294A2 (en) 2003-10-29
ZA200305097B (en) 2004-08-12
WO2002059610A3 (en) 2003-08-14
NO20032781D0 (no) 2003-06-18
WO2002059610A2 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
NO20032781L (no) Anvendelse av overekspresjon av laminin-alfa-4-subenhet som en diagnostiskog prognostisk indikator for maligne tumorer
KR101192297B1 (ko) 간암에 대한 신규 바이오마커 및 그의 용도
Bai et al. Survival impact of psammoma body, stromal calcification, and bone formation in papillary thyroid carcinoma
Shang et al. VEGF is up-regulated by hypoxic stimulation and related to tumour angiogenesis and severity of disease in oral squamous cell carcinoma: in vitro and in vivo studies
Zhou et al. Up-regulation of SERPINA3 correlates with high mortality of melanoma patients and increased migration and invasion of cancer cells
Ikuta et al. Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
Musumarra et al. Potentialities of multivariate approaches in genome‐based cancer research: identification of candidate genes for new diagnostics by PLS discriminant analysis
Yamashita et al. A potential contribution of altered cathepsin L expression to the development of dermal fibrosis and vasculopathy in systemic sclerosis
Guo et al. Association between expression of MMP‐7 and MMP‐9 and pelvic lymph node and para‐aortic lymph node metastasis in early cervical cancer
Song et al. Loss of nuclear BAP1 expression is associated with poor prognosis in oral mucosal melanoma
Soikkeli et al. Systematic search for the best gene expression markers for melanoma micrometastasis detection
Vasala et al. Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2: TIMP-2) as prognostic markers in bladder cancer
Morelli et al. Evaluation of the balance between angiogenic and antiangiogenic circulating factors in patients with breast and gastrointestinal cancers.
Wolff et al. Transforming growth factor‐β1 serum concentration
Gurluler et al. The role of preoperative serum levels for Dickkopf-related protein 1 as a potential marker of tumor invasion in patients with stage II and III colon cancer
Motegi et al. Evidence of a bi-phasic effect of thrombospondin-1 on angiogenesis
WO2001004343A3 (en) A method for determining the prognosis of cancer patients by measuring levels of bag expression
KR102356676B1 (ko) 아스프로신을 포함하는 췌장암 진단용 바이오마커 및 이의 이용
WO2010085124A3 (ko) 간암진단과 재발 및 생존 예측용 마커, 이를 포함한 키트 및 상기 마커를 이용한 간암환자 예후 예측
Kaba et al. Dickkopf-1 levels in Turkish patients with bladder cancer and its association with clinicopathological features
Kondoh et al. Gene expression signatures that classify the mode of invasion of primary oral squamous cell carcinomas
NO20032391L (no) Ekspresjonsanalyse av KIAA-nukleinsyrer og polypeptider anvendelige i diagnose og behandling av prostatakreft
Attis et al. Differential expression of N-cadherin distinguishes a subset of metastasizing desmoplastic melanomas
Yuan et al. Clinical significance of exosomal long noncoding RNA DANCR as a novel serum-based diagnostic and prognostic biomarker in osteosarcoma

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application